Your trusted destination for CME, CPD & Medical Education across the Middle East.
The PLASMA Masterclass is a premier, CME-accredited regional scientific congress designed specifically to translate the latest international breakthroughs in plasma cell dyscrasias and hematologic oncology directly into practical, real-world clinical decision-making across the Gulf region. Centered on advancing clinical excellence in the treatment and comprehensive management of multiple myeloma, AL amyloidosis, and related plasma cell disorders, this high-level educational forum convenes consultant hematologists, medical oncologists, hematopoietic stem cell transplantation (HSCT) specialists, clinical pharmacologists, specialized laboratory pathologists, and multidisciplinary oncology nursing teams. As the therapeutic landscape for plasma cell malignancies evolves at an unprecedented pace, the masterclass serves as an indispensable bridge between cutting-edge global clinical trial data, regulatory approvals, and everyday bedside protocols tailored to the unique clinical demographics of regional healthcare systems. The masterclass curriculum delivers an intensive, high-yield examination of the entire continuum of multiple myeloma care, spanning early risk stratification, frontline management, and long-term disease monitoring. Key instructional modules focus on the practical implementation of novel daratumumab-based quadruplet induction regimens, optimal timing for autologous stem cell transplantation (ASCT), risk-adapted consolidation and maintenance paradigms, and the evolving clinical role of minimal residual disease (MRD) negativity assessment in guiding treatment cessation or escalation. Special emphasis is dedicated to navigating the complex landscape of relapsed/refractory multiple myeloma (RRMM), providing attending clinicians with evidence-based decision frameworks for deploying next-generation targeted agents, bispecific T-cell engagers (BiTEs), and chimeric antigen receptor (CAR) T-cell therapies. Furthermore, dedicated modules address critical supportive care strategies, including bisphosphonate therapy for bone disease, renal impairment management, infection prophylaxis during intensive immunotherapy, and proactive adverse-event management protocols to optimize treatment adherence and patient quality of life. Through a dynamic mix of keynote lectures delivered by global key opinion leaders, interactive "Meet the Expert" small-group breakout discussions, and challenging real-world case debates, the PLASMA Masterclass fosters an environment of rigorous peer-to-peer exchange and regional consensus building. Attending delegates analyze challenging clinical scenarios—such as managing high-risk cytogenetics, frail or elderly populations, and multi-class refractory disease—to refine their diagnostic precision and therapeutic selection. By bringing together international pioneer researchers alongside prominent regional clinical leaders, the meeting equips multidisciplinary oncology teams with actionable, evidence-based management algorithms and updated clinical tools necessary to standardize care pathways, optimize patient safety, and significantly extend long-term survival outcomes for patients with plasma cell disorders across the region.
Exploring the latest advancements and clinical outcomes of CAR T-cell therapies in myeloma patients.
Understanding the role and efficacy of bispecific antibodies in relapsed and refractory settings.
Reviewing new drug classes and targeted therapies currently in clinical trials.
Utilizing genomic data to risk-stratify patients and personalize treatment plans.
The prognostic value of MRD monitoring and its impact on treatment decisions.
Optimizing induction, consolidation, and maintenance therapies for newly diagnosed patients.
Evidence-based sequencing of therapies for patients with relapsed or refractory multiple myeloma.
Strategies for managing treatment-related toxicities and improving patient quality of life.
Secure your seat and earn full credit eligibility with encrypted checkout.
Secure payment processing & PCI-aligned flow